奥拉氟沙星（HSR - 903）在小鼠全身及泌尿系统感染中的体内活性

The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.

作者信息

Yoshizumi S, Takahashi Y, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K

机构信息

Department of Microbiology, Toho University School of Medicine, Tokyo. Research Department, Research & Development Division, Hokuriku Seiyaku Co., Ltd, Fukui, Japan.

出版信息

J Antimicrob Chemother. 2001 Jul;48(1):137-40. doi: 10.1093/jac/48.1.137.

DOI:10.1093/jac/48.1.137

PMID:11418525

Abstract

The in vivo activity of olamufloxacin (HSR-903), a new fluoroquinolone, was evaluated and compared with ciprofloxacin, sparfloxacin and levofloxacin. Olamufloxacin was active against systemic infection in mice inoculated with both Gram-positive and -negative bacteria. Olamufloxacin had equal efficacy for experimental urinary tract infections in mice caused by Pseudomonas aeruginosa.

摘要

对新型氟喹诺酮类药物奥拉氟沙星（HSR - 903）的体内活性进行了评估，并与环丙沙星、司帕沙星和左氧氟沙星进行了比较。奥拉氟沙星对接种革兰氏阳性和阴性细菌的小鼠全身性感染具有活性。奥拉氟沙星对由铜绿假单胞菌引起的小鼠实验性尿路感染具有同等疗效。